Heptanoate

Heptanoate

SCHEMBL392645

C1CCCC1.CCCCCCC(=O)O

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.85
PPARG P37231 7/20 0.85
PPARD Q03181 7/20 0.85
PPARA Q07869 7/20 0.85
HDAC11 Q96DB2 5/20 0.85
TSHR P16473 4/20 0.85
PTPN1 P18031 3/20 0.85
FABP4 P15090 3/20 0.85
ALDH1A1 P00352 2/20 0.85
TLR2 O60603 2/20 0.85
TDP1 Q9NUW8 2/20 0.85
KMT2A Q03164 2/20 0.85
ALOX15 P16050 2/20 0.85
HSD17B10 Q99714 2/20 0.85
SLC22A6 Q4U2R8 1/20 0.85
SLC22A8 Q8TCC7 1/20 0.85
MEN1 O00255 1/20 0.85
ESR1 P03372 1/20 0.85
PDE4A P27815 1/20 0.85
PDE3A Q14432 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Octanoic Acid SCHEMBL28964404 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Decanoic Acid SCHEMBL16537764 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Decanoic Acid SCHEMBL28964393 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Octanoic Acid SCHEMBL28110503 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Nonanoate SCHEMBL11417493 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Octanoic Acid SCHEMBL25268586 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Myristic Acid SCHEMBL28454439 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Stearic Acid SCHEMBL1148214 1.00 GPR84 (0.85) GPR84PPARGPPARDPPARAHDAC11
Stearic Acid SCHEMBL28203009 0.98 GPR84 (0.81) GPR84PPARGPPARDPPARAHDAC11
Myristic Acid SCHEMBL28000481 0.98 GPR84 (0.81) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180177798-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH ALLERGAN INC (US) 2018-06-28 US claimed
US-20150328108-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH ALLERGAN INC (US) 2015-11-19 US claimed
US-20140371320-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH ALLERGAN, INC. (US) 2014-12-18 US claimed
US-20130011354-A1 Compositions For Enhancing Hair Growth ALLERGAN, INC. (US) 2013-01-10 US claimed
US-20120322882-A1 Compositions And Methods For Stimulating Hair Growth ALLERGAN, INC. (US) 2012-12-20 US claimed
CN-102724951-A Compositions and methods for stimulating hair growth ALLERGAN INC 2012-10-10 CN claimed
EP-2498784-A2 COMPOSITIONS FOR ENHANCING HAIR GROWTH Allergan, Inc. (US) 2012-09-19 EP claimed
EP-2498783-A2 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH Allergan, Inc. (US) 2012-09-19 EP claimed
US-8101161-B2 Method of enhancing hair growth ALLERGAN, INC. (US) 2012-01-24 US claimed
US-20110124736-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH ALLERGAN, INC. (US) 2011-05-26 US claimed
EP-2250996-A2 Method of enhancing hair growth ALLERGAN, INC. (US) 2010-11-17 EP claimed
EP-2023769-A1 EYELASH APPLICATOR AND METHOD Allergan, Inc. (US) 2009-02-18 EP claimed
US-7351404-B2 Using a cyclopentane compound ALLERGAN, INC. (US) 2008-04-01 US claimed
US-20080041749-A1 Re-closable vessel system for repeat administration of a drug product and method ALLERGAN, INC. 2008-02-21 US claimed
WO-2007143568-A1 EYELASH APPLICATOR AND METHOD ALLERGAN, INC. (US) 2007-12-13 WO claimed
US-20070286890-A1 Eyelash applicator and method ALLERGAN, INC. 2007-12-13 US claimed
US-20070282006-A1 Method of enhancing hair growth ALLERGAN, INC. 2007-12-06 US claimed
EP-1471876-A1 METHOD OF ENHANCING HAIR GROWTH Allergan, Inc. (US) 2004-11-03 EP claimed
WO-2003066008-A1 METHOD OF ENHANCING HAIR GROWTH ALLERGAN, INC. (US) 2003-08-14 WO claimed
US-20030147823-A1 Using a cyclopentane compound ALLERGAN, INC. 2003-08-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282006-A1 Method of enhancing hair growth FGF1, CYP21A2, HDGF GPR84 1875/4885PPARG 365/4885PPARD 652/4885
US-20130011354-A1 Compositions For Enhancing Hair Growth FGF1, HDGF, FGF2 GPR84 861/4885PPARG 463/4885PPARD 1047/4885
US-20120322882-A1 Compositions And Methods For Stimulating Hair Growth FGF1, HDGF, FGF2 GPR84 600/4885PPARG 481/4885PPARD 1107/4885
US-20180177798-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH FGF1, HDGF, FGF2 GPR84 765/4885PPARG 519/4885PPARD 1221/4885
US-20150328108-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH FGF1, HDGF, FGF2 GPR84 765/4885PPARG 519/4885PPARD 1221/4885
US-20070286890-A1 Eyelash applicator and method SLC39A3, SLC39A11, GHRHR GPR84 697/4885PPARG 609/4885PPARD 562/4885
US-20140371320-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH FGF1, HDGF, FGF2 GPR84 765/4885PPARG 519/4885PPARD 1221/4885
US-20110124736-A1 COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH FGF1, HDGF, FGF2 GPR84 765/4885PPARG 519/4885PPARD 1221/4885
US-20030147823-A1 Using a cyclopentane compound HSD3B1, HSD3B2, CYP21A2 GPR84 1725/4885PPARG 318/4885PPARD 487/4885
US-20080041749-A1 Re-closable vessel system for repeat administration of a drug product and method KDR, HCAR2, TBXA2R GPR84 465/4885PPARG 313/4885PPARD 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.